{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:21:56Z","timestamp":1792963316752,"version":"4.5.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Peloton Advantage, LLC"},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,17]]},"DOI":"10.1093\/asj\/sjaa101","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T12:08:40Z","timestamp":1592222920000},"page":"NP708-NP709","source":"Crossref","is-referenced-by-count":4,"title":["Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA Patient-Reported Outcome Guidance"],"prefix":"10.1093","volume":"40","author":[{"given":"Vaishali","family":"Patel","sequence":"first","affiliation":[{"name":"Allergan plc, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lee","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Silberberg","sequence":"additional","affiliation":[{"name":"Allergan plc, Marlow, Buckinghamshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"2020112411463302200_CIT0001","article-title":"Significantly increased patient satisfaction following liquid formulation abobotulinumtoxinA treatment in glabellar lines: FACE-Q outcomes from a phase 3 clinical trial","author":"Ascher","year":"2019","journal-title":"Aesthet Surg J."},{"key":"2020112411463302200_CIT0002","article-title":"A structured review of patient-reported outcome measures used in cosmetic surgical procedures","author":"Morley","year":"2012"},{"key":"2020112411463302200_CIT0003","author":"US Food and Drug Administration","year":"2009"},{"issue":"2","key":"2020112411463302200_CIT0004","doi-asserted-by":"crossref","DOI":"10.1093\/asjof\/ojz015","article-title":"The psychological impacts of upper facial lines: a qualitative, patient-centered study","volume":"1","author":"Dayan","year":"2019","journal-title":"Aesthet Surg J Open Forum."},{"issue":"4","key":"2020112411463302200_CIT0005","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jocd.12117","article-title":"The impact of upper facial lines and psychological impact of crow\u2019s feet lines: content validation of the Facial Line Outcomes (FLO-11) Questionnaire","volume":"13","author":"Yaworsky","year":"2014","journal-title":"J Cosmet Dermatol."},{"issue":"4","key":"2020112411463302200_CIT0006","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/jocd.12166","article-title":"Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: facial line satisfaction questionnaire","volume":"14","author":"Pompilus","year":"2015","journal-title":"J Cosmet Dermatol."},{"key":"2020112411463302200_CIT0007","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000001779","article-title":"Pooled subject-reported outcomes from 2 phase 3 studies of onabotulinumtoxinA for simultaneous treatment of forehead and glabellar lines","author":"Ogilvie","year":"2019","journal-title":"Dermatol Surg."}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/asj\/article-pdf\/40\/12\/NP708\/34479413\/sjaa101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/asj\/article-pdf\/40\/12\/NP708\/34479413\/sjaa101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T04:40:17Z","timestamp":1606279217000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/40\/12\/NP708\/5857561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":7,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6,15]]},"published-print":{"date-parts":[[2020,11,17]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjaa101","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,6,15]]}}}